Durapatite - Pharmacology
Research News and Information

Sunday, March 21, 2010

In vitro effects of nanophase hydroxyapatite particles on proliferation and osteogenic differentiation of bone marrow-derived mesenchymal stem cells.

13 Sep 2009 Coculturing scaffolds with seeded cells in vitro is an indispensable process for construction of engineered tissues. It is essential to understand effects of the constituent particles of scaffold on seeded cells. In this study, we investigated the ... Read more...

A minimal common osteochondrocytic differentiation medium for the osteogenic and chondrogenic differentiation of bone marrow stromal cells in the construction of osteochondral graft.

30 Aug 2009 To regenerate the complex tissue such as bone-cartilage construct using tissue engineering approach, controllable differentiation of bone marrow stromal cells (BMSCs) into chondrogenic and osteogenic lineages is crucially important. This study ... Read more...

Composite chitosan/nano-hydroxyapatite scaffolds induce osteocalcin production by osteoblasts in vitro and support bone formation in vivo.

30 Aug 2009 There is a significant clinical need to develop alternatives to autografts and allografts for bone grafting procedures. Porous, biodegradable scaffolds based on the biopolymer chitosan have been investigated as bone graft substitutes, and the ... Read more...

Latest indexed articles for 'Durapatite - Pharmacology'

These are the very latest articles for this heading:

• In vitro effects of nanophase hydroxyapatite particles on proliferation and osteogenic differentiation of bone marrow-derived mesenchymal stem cells. 13 Sep 2009
• A minimal common osteochondrocytic differentiation medium for the osteogenic and chondrogenic differentiation of bone marrow stromal cells in the construction of osteochondral graft. 30 Aug 2009
• Composite chitosan/nano-hydroxyapatite scaffolds induce osteocalcin production by osteoblasts in vitro and support bone formation in vivo. 30 Aug 2009
• Multifunctional hydroxyapatite nanofibers and microbelts as drug carriers. 11 Jul 2009
• In vivo study on hydroxyapatite scaffolds with trabecular architecture for bone repair. 13 Jun 2009
• Engineering the bone-ligament interface using polyethylene glycol diacrylate incorporated with hydroxyapatite. 30 May 2009
• In vivo osteogenic capability of human mesenchymal cells cultured on hydroxyapatite and on beta-tricalcium phosphate. 30 May 2009
• Osteoblast adhesion on novel machinable calcium phosphate/lanthanum phosphate composites for orthopedic applications. 30 May 2009
• Surface-dependent modulation of proliferation, bone matrix molecules, and inflammatory factors in human osteoblasts. 30 May 2009
• Stimulatory effect of hydrothermally synthesized biodegradable hydroxyapatite granules on osteogenesis and direct association with osteoclasts. 27 May 2009
• Mesenchymal cell response to nanosized biphasic calcium phosphate composites. 16 May 2009
• L929 fibroblast and Saos-2 osteoblast response to hydroxyapatite-betaTCP/agarose biomaterial. 29 Apr 2009
• Comparative in vivo evaluation of porous and dense duplex titanium and hydroxyapatite coating with high roughnesses in different implantation environments. 29 Apr 2009
• Chemical and topographical influence of hydroxyapatite and beta-tricalcium phosphate surfaces on human osteoblastic cell behavior. 29 Apr 2009
• Study of hydroxyapatite osteoinductivity with an osteogenic differentiation of mesenchymal stem cells. 29 Apr 2009
• Development of nanohydroxyapatite/polycarbonate composite for bone repair. 20 Apr 2009
• Differences in DNA damage pathways induced by two ceramic nanoparticles. 12 Apr 2009
• Point: Hydroxyapatite crystal deposition is intimately involved in the pathogenesis and progression of human osteoarthritis. 30 Mar 2009
• Counterpoint: Hydroxyapatite crystal deposition is not intimately involved in the pathogenesis and progression of human osteoarthritis. 30 Mar 2009
• Effect of different biomaterials on the expression pattern of the transcription factor Ets2 in bone-like constructs. 19 Mar 2009

See a longer list of these articles.

Technical information about 'Durapatite'

Definition: The mineral component of bones and teeth; it has been used therapeutically as a prosthetic aid and in the prevention and treatment of osteoporosis.

Chemical name: Hydroxylapatite (Ca5(OH)(PO4)3)

Registry Number: 1306-06-5

Descriptor UI: D017886

Alternative terms: Durapatite; Hydroxylapatite; Hydroxyapatite; Calcium Hydroxyapatite; Hydroxyapatite, Calcium; Interpore-500; Interpore 500; Interpore500; Alveograf; Calcitite; Ossopan; Osteogen; Periograf; Ossein-Hydroxyapatite Compound; Ossein Hydroxyapatite Compound; Interpore-200; Interpore 200; Interpore200; Osprovit;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Biocompatible Materials;

Tree Number: D01.146.360.050.300.200; D01.578.122.477.300; D01.695.625.675.650.075.025.300.150;

Online Note: use DURAPATITE (NM) to search HYDROXYAPATITE 1981-93

History Note: 94; was HYDROXYAPATITE (NM) 1981-93

Technical Notes: mineral component of bones & teeth; used as a biocompatible material